SCHEMBL3879241

SCHEMBL3879241

CC(c1ccc(CCNC(=O)c2ccc(-c3ccc(Cl)cc3)cc2)cc1)N1CCCC1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 14/20 0.69
CHRM1 P11229 2/20 0.69
HTR2A P28223 2/20 0.69
CYP2D6 P10635 2/20 0.69
SMN1; SMN2 Q16637 3/20 0.54
RAB9A P51151 2/20 0.54
MAPT P10636 2/20 0.54
NPC1 O15118 1/20 0.54
CYP1A2 P05177 1/20 0.54
GAA P10253 1/20 0.54
CYP2C19 P33261 1/20 0.54
GFER P55789 1/20 0.54
PSEN1 P49768 1/20 0.53
PSEN2 P49810 1/20 0.53
APH1B Q8WW43 1/20 0.53
NCSTN Q92542 1/20 0.53
APH1A Q96BI3 1/20 0.53
PSENEN Q9NZ42 1/20 0.53
TP53 P04637 1/20 0.52
ALDH1A1 P00352 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3875273 0.99 MCHR1 (0.69) MCHR1CHRM1HTR2ACYP2D6SMN1; SMN2
SCHEMBL3869879 0.99 MCHR1 (0.69) MCHR1CHRM1HTR2ACYP2D6SMN1; SMN2
SCHEMBL3875329 0.92 MCHR1 (0.60) MCHR1CHRM1HTR2ACYP2D6SMN1; SMN2
SCHEMBL3878657 0.91 MCHR1 (0.59) MCHR1CHRM1HTR2ACYP2D6SMN1; SMN2
SCHEMBL3872340 0.90 ALDH1A1 (0.58) MCHR1CHRM1HTR2ACYP2D6SMN1; SMN2
SCHEMBL3868712 0.90 MCHR1 (0.55) MCHR1CHRM1HTR2ACYP2D6SMN1; SMN2
SCHEMBL3872681 0.89 MCHR1 (0.66) MCHR1CHRM1HTR2ACYP2D6SMN1; SMN2
SCHEMBL3870885 0.89 ALDH1A1 (0.57) MCHR1CHRM1HTR2ACYP2D6SMN1; SMN2
SCHEMBL3881228 0.89 MCHR1 (0.67) MCHR1CHRM1HTR2ACYP2D6SMN1; SMN2
SCHEMBL3870571 0.89 MCHR1 (0.55) MCHR1CHRM1HTR2ACYP2D6SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7601868-B2 Such as 4-(cyclopropylmethoxy)-N-(2-{4-[1-(1-pyrrolidinyl)ethyl]phenyl}ethyl)benzamide having melanin-concentrating hormone antagonistic action, for prophylaxis and/or treatment of obesity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-13 US disclosed
US-7601868-B2 Such as 4-(cyclopropylmethoxy)-N-(2-{4-[1-(1-pyrrolidinyl)ethyl]phenyl}ethyl)benzamide having melanin-concentrating hormone antagonistic action, for prophylaxis and/or treatment of obesity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-13 US disclosed
US-7601868-B2 Such as 4-(cyclopropylmethoxy)-N-(2-{4-[1-(1-pyrrolidinyl)ethyl]phenyl}ethyl)benzamide having melanin-concentrating hormone antagonistic action, for prophylaxis and/or treatment of obesity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-13 US disclosed
US-20060128690-A1 Amine derivative TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-06-15 US disclosed
EP-1593667-A1 AMINE DERIVATIVE Takeda Pharmaceutical Company Limited (JP) 2005-11-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060128690-A1 Amine derivative MC1R, MC2R, MC4R MCHR1 4/4885CHRM1 217/4885HTR2A 94/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.